טוען...

Bridging Tumor Genomics to Patient Outcomes through an Integrated Patient-Derived Xenograft (PDX) Platform

New approaches to optimizing cancer drug development in both the laboratory and the clinic will be required to fully achieve the goal of individualized, precision cancer therapy. Improved preclinical models that more closely reflect the now recognized genomic complexity of human cancers are needed....

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Lung Cancer
Main Authors: Gandara, David R., Mack, Philip. C., Bult, Carol, Li, Tianhong, Lara, Primo N., Riess, Jonathan W., Astrow, Stephanie H., Gandour-Edwards, Regina, Cooke, David T., Yoneda, Ken Y., Moore, Elizabeth H., Pan, Chong-xian, Burich, Rebekah A., David, Elizabeth A., Keck, James G., Airhart, Susan, de Vere White, Ralph W., Liu, Edison T.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4586173/
https://ncbi.nlm.nih.gov/pubmed/25838158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.03.001
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!